Delphia Study for Dementia with Lewy Bodies (DLB)…Enrolling

Description

Palm Beach Neurological Center is participating in a clinical research study to evaluate an investigational drug called “Delphia” for patients suffering from Dementia with Lewy Bodies. An investigational drug is not yet approved for use by the public. Doctors perform these studies to make sure it is safe and to see if it is helpful for patients with Dementia with Lewy Bodies.

Alzheimer’s Prevention Initiative (API) Generation Study 2…Enrolling

Description

Palm Beach Neurological Center is participating in a global clinical research study to prevent or delay Alzheimer’s disease in cognitively healthy, older individuals that have been identified with one or two major genetic risk factors for the onset of Alzheimer’s disease.

The Generation Study 2 is a randomized, double-blind, placebo-controlled trial that tests  whether the BACE inhibitor CNP520 can prevent or delay the symptoms of Alzheimer’s in people at a particularly higher risk due to their age. 

Potential Treatment for Early Onset Alzheimer’s…Ongoing

Description

A global clinical research study assessing the effectiveness and safety of an investigational medication designed to slow the progression of early Alzheimer’s disease.

The ENGAGE study is split into two phases: a placebo-controlled phase, and an optional long-term extension phase.

In the placebo-controlled phase, eligible participants will have a 2-in-3 chance of receiving the investigational medication and a 1-in-3 chance of receiving the placebo.

The MissionAD study for early stages of Alzheimer’s disease…Currently Enrolling

Description

The MissionAD study program is a clinical research program testing an investigational drug for the early stages of Alzheimer’s disease. (“Investigational” means the drug isn’t yet approved for use by the public.) Doctors are studying this investigational drug to make sure it is safe and to see if it may help people with Alzheimer’s disease in the future.

IDEAS PET Imaging Study…Ongoing Study

Description

The “IDEAS” Study stands for Imaging Dementia-Evidence for Amyloid Scanning. The purpose of this study is to improve the way doctors are able to take images of the brain and better treat dementia and memory-related conditions.

Over 8,000 medicare patients are expected to be in the study, and experienced scientists are conducting it with the Alzheimer’s Association and the American College of Radiology Imaging Network (ACRIN).

Alzheimer’s Disease and Sleep Problems… Complete

Description

Many people who have Alzheimer’s also have irregular patterns of sleeping at night and napping during the day. A clinical research study is studying an investigational medication in people with Alzheimer’s disease and sleep problems.

Qualified study volunteers may receive:

  • Study medication
  • Study-related medical care
  • Transportation reimbursement may be available

You may qualify to participate if you:

  • Are 60 to 90 years old
  • Have Alzheimer’s disease
  • Have trouble sleeping at night and napping a lot during the day
  • Have a caregiver who is with you more than 10 hours per week

For more information about this research study call: (561) 282-5546 or email using form below:

 

Dementia with Lewy Bodies (DLB) Research Study…Complete

Dementia with Lewy Bodies (DLB) affects over 1 million people in the United States. It is caused by the buildup of abnormal protein clusters, known as “Lewy Bodies,” within the brain and is characterized by fluctuations in cognitive ability, particularly alertness and attention. Many dementia with Lewy Bodies patients also have visual hallucinations and REM sleep behavior disorder.

Parkinson’s Research Study…Complete

Most individuals with Parkinson’s disease use levodopa as treatment. It is usually taken in pill form, however long-term usage can lessen the effectiveness of the drug leading to off episodes. In these off episodes, individuals with Parkinson’s suffer from slowness, stiffness and tremors. CVT-301, the medication being evaluated in this study, is a powder form [...]

Eisai / Mild Cognitive Impairment or Mild Alzheimer’s Disease…Complete

What is Mild Cognitive Impairment (MCI)?

Mild Cognitive Impairment is a condition in which a person has memory loss or thinking problems that are worse than those caused by normal aging, but not bad enough to interfere with daily activities.  A person with MCI has a higher risk of developing Alzheimer’s disease,

Mild to Moderate Alzheimer’s Disease Treated with Donepezil…Complete

Randomized, double-blind, placebo-controlled, fixed dose study of Lu AE58054 in patients with mild to moderate Alzheimer’s disease treated with Donepezil.

This is a 28 week study in which qualified participants will take the investigational medication or placebo ( a dummy capsule without an active ingredient ) once daily by mouth.

Potential patients must have been receiving a drug containing Donepezil for the last 6 months,

12